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clinicopathological parameters was tested by Chi-square test, two-sided 
Fisher’s exact test, and Cox regression using SPSS version 12.0 and 
STATA version 7.0 software. 
Result: Overall, 36 amplicons, 3 homozygous deletions, and 17 
minimally altered regions (MAR) common to many lung cancers were 
identiﬁed. Among them, genomic changes on 13q21, 1p32, Xq and Yp 
were found to be signiﬁcantly associated with clinical features, such 
as age, stage, and disease recurrence. Kaplan-Meier survival analysis 
revealed that genomic changes on 10p, 16q, 9p, 13q, 6p21 and 19q13 
were associated with poor survival. Multivariate analysis showed that 
alterations on 6p21, 7p, 9q, and 9p were remained as independent 
predictors for poor outcome. In addition, signiﬁcant correlations were 
observed for 3 pairs of MARs (19q13 and 6p21, 19p13 and 19q13, and 
8p12 and 8q11), which indicated their possible collaborative roles. We 
examined the expression level of ECT2, one of the genes located in the 
most recurrently gained region on 3q26 by real-time qPCR. Expression 
of ECT2 was generally appeared to be up-regulated in NSCLCs. 
Conclusion: These results show that the novel genomic alterations 
identiﬁed in this study along with their clinicopathological implications 
would be useful to elucidate molecular mechanisms of lung cancer and 
to identify reliable biomarkers for clinical application.
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Background: Lung cancer is a leading cause of cancer death world-
wide. Non-small cell lung cancer (NSCLC) accounts for ~85% of lung 
cancers, with squamous cell carcinoma (SqCC) and adenocarcinoma 
(AC) comprising the two main subtypes. SqCC typically develops in 
the central airways, and AC characteristically originates in the periph-
eral lung. Although these subtypes can be distinguished readily at the 
histological level, knowledge of the genetic mechanisms underlying 
their differences will lead to the development of novel disease speciﬁc 
therapeutic strategies. Previous studies suggest that distinct patterns 
of genomic alteration exist for AC and SqCC. However, the speciﬁc 
genes responsible for the different tumor phenotypes remain largely 
unknown. Initial gene expression proﬁling studies have yielded some 
insight into the tumor subtypes and are able to segregate tumors into 
histologic groupings based on multi-gene models. Since not all gene 
expression changes are causal to disease development, it is challenging 
to distinguish critical events from reactive changes through global gene 
expression proﬁles alone. Thus, an integrative approach is necessary to 
fully understand the causal genetic events and downstream effects on 
disease phenotype. 
Objective: To comprehensively identify the underlying molecular 
differences between SqCC and AC using an integrative genome and 
transcriptome analysis. The discovery of genes differentially altered in 
each phenotype may clarify mechanisms of tumor differentiation and 
identify novel molecular targets for early diagnosis and therapy 
Methods: A whole genome tiling path CGH array was used to gener-
ate copy number proﬁles of 103 AC and 58 SqCC tumors. This array 
allows the detection of small segmental alterations such as micro-am-
pliﬁcations and focal deletion which may have been undetected by con-
ventional cytogenetic methods. Array data was visualized using SeeGH 
software and subjected to a smoothing computational algorithm to 
determine chromosomal areas of gain and loss. The resulting frequen-
cies of alteration for each locus were compared between AC and SqCC 
using Fisher’s Exact Test and regions with difference of p<0.001 were 
considered statistically signiﬁcant. This genomic data was then inte-
grated with genome wide expression data to identify genes deregulated 
as a result of copy number alterations speciﬁc to each NSCLC subtype. 
Results: Subtype speciﬁc copy number changes were identiﬁed. 
Regions of alteration disparity were mapped to chromosomes arms 2p, 
3q, 4p, 4q, 8p, 12p, 19p, 19q, 20p and 22q. Analysis of expression data 
for the genes in these regions identiﬁed 183 unique genes differentially 
expressed between the subtypes as a result of copy number changes. 
Clustering and principle component analysis conﬁrmed that these 
gene signatures were able to accurately delineate the disease subtypes. 
Grouping of these genes by biological function showed that many im-
portant pathways are differentially altered in AC and SqCC in disease 
speciﬁc ways. 
Conclusions: Whole genome array CGH comparison between AC 
and SqCC tumor genomes identiﬁed tumor subtype-speciﬁc genetic 
alterations. Integration of gene expression data delineated genes and 
pathways that could be important in phenotype differentiation. Charac-
terization of these genes is now underway with the aim of deﬁning new 
molecular targets for early diagnosis and treatment.
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Background: Prevention of primary tumour development remains to 
be the foundation for lung cancer control. Chemoprevention is deﬁned 
as a pharmacologic intervention to suppress or reverse the carcinogenic 
process, and effective chemoprevention agents for lung cancer are 
needed. Due to effective public health campaigns for tobacco control, 
many lung cancers now arise in former smokers. We hypothesise that 
genomic changes common to current and former smokers represent 
authentic, permanent molecular changes altered by tobacco-smoke and 
may therefore represent crucial aberrations that lead to tobacco-smoke 
related lung carcinogenesis. Hence, the identiﬁcation of these causal 
smoking-related lung cancer genes represent drug-able targets for the 
development of novel or natural chemoprevention agents for the pre-
vention of lung cancer in former smokers.
Methods: We analysed a total of 84 fresh tumour tissues from resected 
primary non-small cell lung carcinomas (NSCLCs): 46 current smok-
ers (still smoking or quit less than one year prior to surgical resec-
tion), 26 former smokers (quit more than ten years prior to surgical 
resection), and 12 never smokers (smoked less than 100 cigarettes 
in lifetime). All smokers had at least 20 pack-years smoking history. 
Patients were matched on age (±10 years) and tobacco-smoke exposure 
(±10 pack-years). There was no signiﬁcant difference in sex, histol-
ogy, age or tobacco-smoke exposure between smoking groups. High 
molecular weight tumour DNA was digested, ﬂuorescently labelled and 
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hybridised against female human genomic DNA to a high resolution 
array-Comparative Genomic Hybridisation (aCGH) platform contain-
ing ~43,000 probes (Agilent 44K Human Whole-Genome 44B arrays). 
Genomic regions with signiﬁcant copy-number variation (CNV) (DNA 
gain/loss) were identiﬁed using an aberration detection algorithm (CGH 
Analytics V3.4).
Results: The most frequent CNVs in current smokers were gain 
of 1q21.1-q24.2 and 5p15.33-p12 (>60% of tumours) and loss of 
8p23.3-p12 and 13q12.11-q34 (>20% of tumours). The most frequent 
CNVs in former smokers were gain at 1q25.2-q44 and 17q11.2-q25.3 
(>50% of tumours) and loss at 13q12.11-q21.2 and 21q11.2-q22.3 
(>20% of tumours). The most frequent CNVs in never smokers were 
gain at 7p22.3-p11.2 (>50% of tumours) and loss at 8p23.3-p11.22 
and 13q13.3-q14.3 (>50% of tumours). CNVs present in both current 
and former smokers were compared to identify recurrent (occurring in 
>30% of tumours, both smokers and former smokers) genomic aber-
rations. Frequent copy-number gain was observed at 1q21.1-q31.3, 
1q31.1-q44, 3q26.1-q29, 5p15.33-p12, 7p22.1-p11.2, 7p11.1-q36.2, 
and 17q21.2-q25.3. Gain at 1q25.2-q31.3 occurred in more than 50% 
of current and former smokers, yet was rarely gained in never-smokers 
(8%).
Conclusions: In the chaos that occurs in lung cancer cells that develop 
in current smokers (with continued carcinogenic exposure and therefore 
high lung cancer risk), those aberrations in common with lung cancer 
cells that develop in former smokers (with no further carcinogenic 
exposure and therefore lower but persistent lung cancer risk) may 
represent irreversible causative genetic damage. Genes located in these 
aberrations represent strong chemoprevention targets. Our analysis has 
identiﬁed several loci frequently aberrant in both current and former 
smokers. These loci are now being further studied to identify the poten-
tial gene targets of aberration.
Funding: IASLC Lung Cancer Fellowship, NHMRC (338602, 338200), 
TPCH (FRC0205-23).
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Objective: The Danish lung cancer screening trial is a randomized trial 
comparing CT screening with no screening. The trial is done with the 
NELSON trial in the Netherlands, Europe. The ﬁnal end point is lung 
cancer mortality.
Methods: From 2004 to 2006 4104 Danish smokers and previous 
smokers were randomized to either screening with annual low dose CT 
scans for 5 years or no screening. A history of cigarette smoking of at 
least 20 pack years was required. All had lung function tests, and ques-
tionnaires regarding psychosocial consequences of screening, smoking 
and smoking cessation at randomization and planned annually. 
All scans are performed with a 16 detector row CT scanner at low dose 
levels, and viewed independently by two board certiﬁed radiologists. 
Nodules identiﬁed in the baseline year were considered prevalence 
nodules. 
Nodules were classiﬁed according to size and other characteristic: 
• Nodules smaller than 5 mm and calciﬁed nodules with a maximal 
diameter up to 20 mm were just tabulated. 
• Uncalciﬁed nodules with a diameter between 5 and 15 mm were 
re-scanned after 3 months; 1) if the size was stable or reduced no 
further action was taken.2) If the nodule grew it was referred for 
invasive workup, as were uncalciﬁed nodules larger than 15 mm.
CT with contrast and PET CT was performed before any invasive 
procedures. 
Results: At baseline 177 persons had nodules larger than 5 mm on the 
ﬁrst scan, and almost all were rescanned after 3 months. 
• Seventeen individuals (0.8%) with a suspicious lung nodule were 
referred to surgical exploration and all turned out to have cancer. 
One stage IA patient had segmental resection (adenocarcinoma 
(ACL) dominated by BAC features), ten patients (6 stage IA, 3 stage 
IB and 1 stage IIIB) had lobectomy (9 ACL and 1 squamous cell 
carcinoma (SQC), one stage IIIA had pneumonectomy (ACL).The 
remaining ﬁve patients were in stage IIIA after diagnostic evaluation 
and received chemotherapy (3 non small cell lung carcer (NSCLC), 
probably ACL, 1 ACL, 1 SQC). 
• Seventy one percent had ACL, 12% SQC and 17% NSCLC. No 
SCLC was diagnosed.
• Twelve of 17 lung cancers at base line were treated surgically, 8 of 
these were treated by VATS resection.
• One participant had a benign hamartoma (4 cm) removed by VATS 
local resection and one had a diagnostic VATS on suspicion of me-
sothelioma which turned out to be pleural tuberculosis.
• Rate of false positive diagnoses was 8,6 %. 
• In the control group so far one patient had a lobectomy (ACL) stage 
1, one had a pneumonectomy for a stage IIIA lung cancer, two had 
oncological treatment for stage 4 disease (ACL) and one patient died 
with lung cancer stage IIIB (ACL). 
Conclusion: Screening facilitates minimal invasive treatment and can 
be performed with a low rate of false positive diagnoses. 
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